2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Phospholipase
  5. Phospholipase C Isoform

Phospholipase C

Phospholipase C (PLC) hydrolyzes PI(4,5)P2 to generate IP3 and DAG, positioning PLC as a central enzyme in phosphoinositide metabolism and intracellular signal transduction[1]. Mechanistically, IP3 regulates intracellular Ca2+ release, while DAG supports protein kinase C activation, linking receptor stimulation to calcium signaling, proliferation, differentiation, and motility[1][2]. In mammals, PLC enzymes form structurally defined isozyme classes with shared catalytic activity but distinct activation mechanisms and physiological functions[1][3]. Compared with PLCβ, which couples strongly to G-protein-coupled receptor signaling, PLCγ functions downstream of receptor and non-receptor tyrosine kinases and contains γ-specific regulatory domains that support isoform-specific signaling[4]. Disease-focused studies link PLCγ dysfunction to immune disorders and cancer, while PLCγ2 mutations connect immune dysregulation, malignancy, and neurodegeneration models[4][5]. For experimental applications, U73122 has been widely used to probe PLC-dependent signaling, but purified-enzyme studies showed direct PLC activation by U73122, so inhibitor-based experiments require careful controls[6][7].

Phospholipase C Related Products (9):

Cat. No. Product Name Effect Purity
  • HY-P4821
    pTH (1-34) amide (human)
    		Activator 99.78%
    PTH (1-34) amide human is a type 1 PTH/PTHrP receptor agonist. PTH (1-34) amide human activates adenylate cyclase and phospholipase C pathways, thereby mediating mineral ion homeostasis and bone metabolism regulation. PTH (1-34) amide human increases serum calcium, decreases serum phosphorus, regulates renal excretion, while inducing the inhibition of endogenous PTH (1-84) and the increase of 1,25-dihydroxyvitamin D2 and bone resorption. PTH (1-34) amide human stimulates phosphatidylcholine hydrolysis via phospholipase D mediation, and its hypercalcemic effect is inhibited by human PTH-(7-84). PTH (1-34) amide human can be used in the research of diseases related to humoral hypercalcemia of malignancy.
  • HY-P2817
    Phospholipase C
    Phospholipase C (PLCs) is a class of phospholipases. Phospholipase C participates in cellular signaling and regulation by virtue of its ability to hydrolyze membrane phospholipids into di-acyl-glycerol (DAG) and inositol triphosphate (IP3), which further causes the activation of other signaling pathways involved in various processes, including immune response.
  • HY-P2139
    Ranakinin
    		Activator
    Ranakinin is a NK1R agonist. Ranakinin inhibits the binding of selective NK1 radioligands to NK1 receptors. Ranakinin activates phospholipase C (Phospholipase C), thereby enhancing polyphosphoinositide hydrolysis. Ranakinin stimulates inositol phosphate production and reduces membrane polyphosphoinositide levels. Ranakinin stimulates corticosterone and aldosterone secretion.
  • HY-177218
    M119
    		Inhibitor
    M119 (NSC 119910) is a selective Gβγ-subunit inhibitor. M119 selectively potentiates μ-opioid-dependent antinociception. M119 inhibits μ-receptor-dependent phospholipase (PLC) activation. M119 can enhance opioid analgesia and attenuate its acute tolerance and dependence in mice. M119 can be used for pain research.
  • HY-162613
    ASM-IN-2
    		Inhibitor
    ASM-IN-2 (Compound 46) is a potent ASM inhibitor with an IC50 value of 0.87 μM, displaying good drug-like properties. ASM-IN-2 involves in multiple antidepressant mechanisms of actionin, which are associated with a decline of ceramide. It demostrates remarkable antidepressant effects in the CUMS-induced mouse, which is promising for research in the field of antidepressant drugs.
  • HY-182452
    U 84569
    		Inhibitor
    U 84569 is a potent low-Km cAMP-dependent Phosphodiesterase inhibitor, with an IC50 value of 300 nM in platelet cytosol. By inhibiting phosphodiesterase and elevating cAMP levels, U 84569 indirectly blocks receptor-mediated Phospholipase C activation, thereby inhibiting platelet aggregation.
  • HY-108654
    PSB 0474
    PSB 0474 (3-phenacyl-UDP) is a UDP (HY-113359) analog and selective P2Y6 receptor agonist, with an EC50 value of 70 nM for the hP2Y6 receptor. PSB 0474 activates Phospholipase C-coupled receptors to increase intracellular inositol phosphate levels. PSB 0474 enhances NO release by upregulating inducible iNOS and induces Apoptosis. PSB 0474 increases micturition frequency in urine of anesthetized rats, without altering bladder contraction amplitude/duration or causing urothelial damage. PSB 0474 can be used in studies related to chronic brain inflammation.
  • HY-186140
    SHP1-IN-2
    		Activator
    SHP1‑IN‑2 is a selective and orally active SHP1 inhibitor. SHP1‑IN‑2 covalently binds to Cys480 of SHP1. SHP1‑IN‑2 elicits potent antitumor immunity and suppresses syngeneic tumor growth. SHP1‑IN‑2 blocks tumor progression in a svngeneic cancer model by activating natural killer cells and cytotoxic CD8＋ T cells, along with reduced T cel l. SHP1‑IN‑2 can be used for cancer‑related research.
  • HY-W778574
    BAPTA tetracesium
    		Inhibitor
    BAPTA tetracesium is a selective and cell-impermeant chelator for calcium. BAPTA tetracesium has high selectivity against magnesium and calcium. BAPTA tetracesium can also inhibit phospholipase C activity independently of their role as Ca2+ chelators.